NeuroVive Pharmaceutical AB | Balance Sheet
Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
39,992.00
49,698.00
96,662.00
93,251.00
28,992.00
25,951
Total Accounts Receivable
1,096.00
1,123.00
2,368.00
1,650.00
1,568.00
1,432
Other Current Assets
513.00
502.00
528.00
1,171.00
1,967.00
1,244
Total Current Assets
41,601.00
51,323.00
99,558.00
96,072.00
32,527.00
28,627
Net Property, Plant & Equipment
457.00
344.00
316.00
274.00
162.00
140
Total Investments and Advances
-
-
1.00
13,102.00
13,102.00
13,101
Long-Term Note Receivable
-
-
148.00
118.00
-
-
Intangible Assets
47,119.00
79,601.00
74,904.00
71,151.00
74,315.00
73,440
Total Assets
89,177.00
131,268.00
174,927.00
180,717.00
120,106.00
115,308
Accounts Payable
4,759.00
14,216.00
5,207.00
6,000.00
7,525.00
Other Current Liabilities
9,775.00
9,211.00
14,941.00
6,413.00
6,735.00
Total Current Liabilities
14,534.00
23,427.00
20,148.00
12,413.00
14,260.00
Total Liabilities
14,534.00
23,427.00
20,148.00
12,413.00
14,260.00
Common Equity (Total)
75,456.00
103,312.00
141,128.00
155,446.00
100,715.00
Total Shareholders' Equity
75,456.00
103,312.00
141,128.00
155,446.00
100,715.00
Total Equity
74,643.00
107,841.00
154,779.00
168,304.00
105,846.00
Liabilities & Shareholders' Equity
89,177.00
131,268.00
174,927.00
180,717.00
120,106.00
Accumulated Minority Interest
813.00
4,529.00
13,651.00
12,858.00
5,131.00
About NeuroVive Pharmaceutical AB
View Profile
